Alcohol Withdrawal Management

Assessment and Screening

The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) is used for assessing withdrawal severity, with a score >8 indicating moderate withdrawal and a score ≥15 indicating severe withdrawal requiring aggressive treatment 1
Screening for infections, acute kidney injury, and extrahepatic organ damage (cardiomyopathy, pancreatitis, nephropathy, neurological complications) is essential for patients with Alcoholic Liver Disease (ALD), as recommended by the American Gastroenterological Association and the European Association for the Study of the Liver 2, 1
Screening for cancer of the aerodigestive tract is also important for patients with ALD, according to the European Association for the Liver 1

Benzodiazepines are the gold standard for alcohol withdrawal syndrome, with long-acting benzodiazepines (diazepam, chlordiazepoxide) providing better protection against seizures and short-acting benzodiazepines (lorazepam, oxazepam) being safer in elderly patients and those with liver dysfunction, as recommended by the American Association for the Study of Liver Diseases 1, 3, 4
The following table outlines the recommended approaches for managing withdrawal based on the CIWA-Ar score:

CIWA-Ar Score	Severity	Recommended Approach
≤7	Mild	Monitor, may not require medication
8-14	Moderate	Initiate benzodiazepine treatment
≥15	Severe	Aggressive benzodiazepine treatment, consider inpatient management [4, 3]

Thiamine supplementation is essential to prevent Wernicke's encephalopathy, particularly in malnourished cirrhotic patients, as recommended by the American Association for the Study of Liver Diseases 3, 5
Nutritional support is crucial, with a recommended caloric intake of 35-40 kcal/kg/day and protein intake of 1.2-1.5 g/kg/day for patients with ALD, according to the American Association for the Study of Liver Diseases 3
The following table outlines the recommended approaches for each phase of treatment:

Phase	Description	Recommended Approach
Initial	Manage withdrawal symptoms with benzodiazepines and nutritional support	Benzodiazepines, thiamine supplementation, and nutritional support [3, 6]
Early Recovery	Start pharmacotherapy (naltrexone, acamprosate, or baclofen) combined with psychosocial interventions	Pharmacotherapy, psychosocial interventions, and ongoing support [3, 7, 6]
Maintenance	Continue medications for 3-12 months with ongoing psychosocial support	Medications, psychosocial support, and regular follow-up [3, 7, 6]

Baclofen is preferred for patients with hepatic impairment, as it improves abstinence rates and decreases relapse, according to the European Association for the Study of the Liver 1, 5
Acamprosate is effective in supporting detoxified, alcohol-dependent patients to maintain abstinence for up to 12 months, and works by reducing withdrawal symptoms and alcohol craving, as stated by the American Association for the Study of Liver Diseases and the National Institute on Alcohol Abuse and Alcoholism 8, 9, 5
Naltrexone reduces heavy drinking days and cravings in patients with alcohol dependence, as recommended by the American College of Physicians, and requires monitoring of liver function tests every 3-6 months 10, 11
Corticosteroids (prednisolone 40 mg/day for 28 days) improve 28-day survival in patients with severe alcoholic hepatitis, as recommended by the American Association for the Study of Liver Diseases 3

Brief interventions using the FRAMES model (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy) are effective in managing ALD, as suggested by the American College of Gastroenterology 3
Group therapy, such as Alcoholics Anonymous, is a useful intervention for patients with ALD, as recommended by the American College of Gastroenterology 3
Motivational enhancement is beneficial for patients ambivalent about alcohol cessation, according to the American College of Gastroenterology 3
Family education and therapy is important for addressing dysfunctional family dynamics in patients with ALD, as suggested by the American College of Gastroenterology 3
Cognitive Behavioral Therapy (CBT) is a first-line psychotherapy approach for addressing depressive thought patterns and drinking behaviors, particularly effective for patients who drink to cope with negative emotions 12, 6, 13
Motivational Interviewing is effective for patients ambivalent about alcohol cessation, helping patients recognize problems and develop commitment to change 14, 13, 7

Prescribing medications without psychosocial support, failing to monitor for medication side effects, not addressing comorbid psychiatric conditions, and discontinuing treatment prematurely are common pitfalls to avoid in the treatment of Alcohol Use Disorder (AUD), as warned by 6, 7